Wednesday, December 25, 2013

Protective Agents for Chemotherapeutic Drugs Induced -Renal Failure


Protective Agents for Chemotherapeutic Drugs Induced -Renal Failure

Editorial  

AUTHOR: Sivakumar J T Gowder

 AFFILIATION: Qassim University, College of Applied Medical Sciences, Buraidah, Kingdom of Saudi Arabia.

 CORRESPONDING AUTHOR: via Sivakumar J T Gowder, Qassim University, College of Applied Medical Sciences,  P.Box-6800, Buraidah -51452, Kingdom of Saudi Arabia; Tel: +966566873969;  Fax: +96663802268;   Email: sivakumargowder@yahoo.com  

Download full text from http://oncodrugs.org/journal/current.php (PDF)

Wednesday, December 11, 2013

Nanostrategies in the war against multidrug resistance in leukemia


Nanostrategies in the war against multidrug resistance in

leukemia

Review Article 

AUTHORS: Alphy Rose-James1, TT Sreelekha1, Suraj K. George2*

AFFILIATIONS: 1Laboratory of Biopharmaceuticals, Division of Cancer Research, Regional Cancer Centre, Thiruvananthapuram-695 011, Kerala, India. 2Dept. of Hematopathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
 

* CORRESPONDING AUTHOR: Dr. Suraj Konnath George PhD. Dept. of Hematopathology. Division of Pathology and Laboratory Medicine. University of Texas MD Anderson Cancer Center. 1515 Holcombe Blvd, Houston, TX 77030, USA. Ph: 001-7137927692   Fax: 001-7137927273. Email: skonnath@mdanderson.org or surajrcc@gmail.com

 Abstract
Chemotherapy is the cornerstone of treatment for haematological malignancies. Despite innovative advances in the understanding of this complex disease, multidrug resistance (MDR) is still a major culprit for the treatment failure, especially in leukemia. Conventional combinatorial therapy is a major decoy to circumvent MDR, but those are frequently thwarted by the evolving intricacies of the cancer paradigm. The advent of nanomedicine has ushered a new era with striking pharmacokinetic drug properties far enough to combat MDR. Physicochemical elements such as co-encapsulation, drug influx, ratiometric drug loading, temporal sequencing on drug release, and selective targeting moiety have been better tailored within the nanotherapeutics to overcome MDR. This review focuses on a plethora of nanostrategies and nanoplatforms which have been developed so far to battle MDR in leukemia.
Download full text (PDF) from OncoDrugs

Thursday, December 5, 2013

Nutritional therapy: multitarget agents to prevent multifactorial diseases


Nutritional therapy: multitarget agents to prevent multifactorial diseases

Editorial  

AUTHORS: Marcello Iriti1* and Elena Maria Varoni2

 

AFFILIATIONS: 1Dipartimento di Scienze Agrarie e Ambientali, Università degli Studi di Milano. 2Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Università degli Studi di Milano.

Donwload full text (PDF) from http://www.oncodrugs.og/journal